Scarica l'app Stockscreener
192.30
1.29%
-2.51
Pre-mercato:
189.70
-2.60
-1.35%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Astrazeneca Plc Borsa (AZN) Ultime notizie
GSK doubles down on oncology as AstraZeneca’s pipeline cranks up - Investors' Chronicle
Nordic Equities in North AmericaAstraZeneca declines 1.2 percent - marketscreener.com
Earnings Preview: AstraZeneca to Report Financial Results Pre-market on April 29 - Moomoo
Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance Singapore
Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
AstraZeneca Advances New Imaging Tool in Targeted Lung Cancer Trial - TipRanks
ASTRAZENECA : JP Morgan reiterates its Buy rating - marketscreener.com
AstraZeneca announces board change as Rene Haas to step down as director - Investing.com
AstraZeneca (NYSE: AZN) board member Rene Haas to step down - Stock Titan
Arm's Haas to leave AstraZeneca board amid new SoftBank role - marketscreener.com
IN BRIEF: Arm's Haas to leave AstraZeneca board amid new SoftBank role - London South East
AstraZeneca Announces Directorate Change: Rene Haas to Step Down - Devdiscourse
AstraZeneca Advances Kidney Care With Ultomiris Breakthrough - Kalkine Media
AstraZeneca to seek accelerated approval of Ultomirisin in IgAN on Phase III data - Clinical Trials Arena
AstraZeneca Advances Kidney Care with Ultomiris Trial Success - Kalkine Media
AstraZeneca (AZN) Seeks Accelerated Approval for Ultomiris in Ig - GuruFocus
T Rowe Price Equity Income Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage - Yahoo Finance
AstraZeneca slides Tuesday, underperforms market - MarketWatch
AstraZeneca's Ultomiris Meets Goal in Rare Kidney Disease Study - Yahoo Finance
AstraZeneca’s Ultomiris Hits Interim Phase III Endpoint In IgAN, Eyes Accelerated Filings - Citeline News & Insights
Seller pressure near £14,350–£14,800 weighs on AstraZeneca stock price - Traders Union
Germany risks missing out on new drugs, AstraZeneca CEO tells paper - Reuters
AstraZeneca's tozorakimab treble puts $5bn sales ceiling in sight, says Citi - Proactive Investors
AstraZeneca (AZN) Reports Positive Interim Results from I CAN Tr - GuruFocus
AstraZeneca Drug Advances Spark Strong Market Attention - Kalkine Media
AstraZeneca’s COPD drug gains third Phase III win - Clinical Trials Arena
AstraZeneca reports Ultomiris meets primary endpoint in IgAN Phase III trial - Investing.com
Ultomiris IgAN Phase III interim success boosts AstraZeneca (AZN) rare kidney portfolio - Stock Titan
AstraZeneca says Ultomiris meets primary endpoint in phase III trial - marketscreener.com
ASTRAZENECA : Gets a Buy rating from JP Morgan - marketscreener.com
Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity by 2030 with the 1st Approved BsADC by 2028 - GlobeNewswire Inc.
Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031Insight on More than 550 Clinical Trials - GlobeNewswire Inc.
Targeted Alpha Therapy Market Landscape Report 2026-2030: Clinical Trials Insights on 30 Drugs - GlobeNewswire Inc.
AstraZeneca receives positive high level results from Phase III I CAN trial - Sharecast.com
AstraZeneca's Ultomiris hits primary endpoint in rare kidney disease trial - Proactive financial news
AstraZeneca reports Ultomiris meets primary endpoint in phase III trial for IgAN at week 34 - marketscreener.com
AstraZeneca's Breakthrough in IgAN Treatment: Ultomiris Triumphs in Phase III Trials - Devdiscourse
AstraZeneca PLC stock (US6549022043): Is its oncology pipeline strong enough to unlock new upside? - AD HOC NEWS
Lobbying Update: $2,280,000 of ASTRAZENECA PHARMACEUTICALS LP lobbying was just disclosed - Quiver Quantitative
AstraZeneca PLC stock (US6549022043): Is its oncology dominance strong enough to drive sustained ups - AD HOC NEWS
AstraZeneca stock slips as weak momentum limits further upside - Traders Union
AstraZeneca (AZN) Achieves Success in Late-Stage COPD Trial for Tozorakimab - GuruFocus
AstraZeneca's tozorakimab delivers reduction in chronic lung disease flare‑ups - Reuters
AstraZeneca PLC stock (US6549022043): Is oncology dominance strong enough to unlock new upside? - AD HOC NEWS
AstraZeneca Builds COPD Case For Tozorakimab With Third Positive Phase III Trial - Citeline News & Insights
Generic Injectables Market Major PlayersAstrazeneca, Baxter - openPR.com
AstraZeneca (AZN) Stock: Tozorakimab Achieves Phase III COPD Success in MIRANDA Study - Blockonomi
AstraZeneca (AZN) Stock: COPD Drug Tozorakimab Hits Phase III Trial Goals - CoinCentral
AstraZeneca (AZN) scores third positive Phase III COPD result for tozorakimab - Stock Titan
COPD patients saw fewer flare-ups in AstraZeneca's third Phase III trial - Stock Titan
AstraZeneca PLC (AZN) Stock Analysis: Eyeing Modest Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Astrazeneca Says Tozorakimab Significantly Lowers COPD in Phase 3 Study - marketscreener.com
AstraZeneca's Tozorakimab meets primary endpoint in "pivotal" trial - marketscreener.com
AstraZeneca reports positive top-line data from Phase III MIRANDA trial - Sharecast.com
Astrazeneca says tozorakimab meets primary endpoint in phase III Miranda trial for COPD - marketscreener.com
AstraZeneca's tozorakimab delivers reduction in chronic lung disease flare-ups - marketscreener.com
AstraZeneca Reports Positive Late-stage Data for Chronic Obstructive Pulmonary Disease Drug Tozorakimab - marketscreener.com
AstraZeneca's tozorakimab delivers sharp reduction in COPD flare-ups - marketscreener.com
AstraZeneca : Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD - marketscreener.com
AstraZeneca PLC stock (US6549022043): Is oncology dominance strong enough to drive sustained upside? - AD HOC NEWS
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD - AstraZeneca
AstraZeneca PLC stock (US6549022043): Is its oncology dominance strong enough to unlock new upside? - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): Is oncology dominance strong enough to drive sustained U.S. in - AD HOC NEWS
1.53%
1.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):